Press Releases September 2, 2026 08:30 AM

Equillium to Participate in Upcoming Investor Conferences

Equillium Announces Participation in Key Investor Conferences to Engage with Stakeholders

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
EQ

Equillium, Inc., a biotech firm focused on therapies for autoimmune and inflammatory disorders, announced its management team's participation in the Cantor Global Healthcare Conference 2026 and the H.C. Wainwright 28th Annual Global Investment Conference. The company plans to conduct presentations, fireside chats, and one-on-one meetings with investors to discuss its pipeline and strategic direction.

Equillium to Participate in Upcoming Investor Conferences
EQ
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Equillium will present at two major investor conferences in September 2026, enhancing visibility among healthcare investors.
  • The management team will engage in fireside chats and one-on-one meetings, providing opportunities for deeper investor interaction.
  • Webcasts of the presentations will be available, increasing accessibility for shareholders and interested parties.

LA JOLLA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences:

Cantor Global Healthcare Conference 2026
Format: Fireside Chat & 1x1 Meetings
Date: Wednesday, September 9, 2026
Time: 9:45 AM EDT
Webcast Link: Here

H.C. Wainwright 28th Annual Global Investment Conference
Format: Company Presentation & 1x1 Meetings
Date: Monday, September 14, 2026
Time: 11:00 AM EDT

Members of the Equillium management team will be available to meet with investors who are registered to attend the conference.

A live webcast of the Cantor fireside chat may also be accessed on the Events & Presentations page, located under the Investor Relations section on equilliumbio.com. A replay of the webcast will be available for approximately 45 days following the conference.

About Equillium
Equillium is a biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders.

For more information, visit www.equilliumbio.com.

Investor Contact 
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com


Risks

  • No new clinical data or product updates were provided, which may limit immediate investor enthusiasm.
  • Uncertainty remains regarding development timelines and regulatory approvals for their novel therapies.
  • Market and sector-specific risks include competition in the biotech space and the challenges of drug development impacting biotechnology and healthcare sectors.

More from Press Releases

Reborn Coffee Receives Nasdaq Notification Regarding Late 10-Q Filing and Continued Listing Requirements Sep 3, 2026 HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy Sep 3, 2026 LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China Sep 3, 2026 Ming Shing Group Holdings Limited Announces Closing of the Acquisition of Meals Through Seasons Limited and Issuance of Consideration Shares and Unsecured Convertible Promissory Notes Sep 2, 2026 Diversified Announces Accretive Acquisition of Birch Sep 2, 2026